Sealants and Adhesives in Surgical Procedures and Surgical Wound Closure
Surgical sealants and adhesives are the products used in surgical procedures for closing incisions, sealing tissues internally, stop bleeding, securing implants to tissues and in post surgical applications like sealing of surgical incision leakage, to control surgical site infections and reinforcing staples or suture line. Surgical sealants and adhesives can be derived from the natural source like fibrin, collagen, gelatin, albumin and others or synthetic source like cyanoacrylate, hydrogels and others.
According to IQ4I analysis, the surgical sealants and adhesives global market is expected to grow at a high single digit CAGR to reach $3,708.5 million by 2024. Surgical sealants and adhesives have huge potential to replace the traditional surgical incision closure products like sutures, staples and ligating clips due to the advantages like simple implementation procedure, shorter application time, less painful to patients, reduction in surgical site infection, better cosmetic outcome with minimum scarring and no need for removal. Some of the factors driving the market are increasing incidence of aging population and prevalence of lifestyle diseases, increase in surgical procedural volume, and advantages of sealants and adhesives over sutures and stapes. However, adverse effects of sealants and adhesives, possible transmission of infectious agents from materials of animal origin, low surgical incision closure strength, high cost of the product, advancements in alternative products like sutures, staples and stringent regulatory approvals are some of the factors hampering the market growth.
The market penetration of surgical sealants and adhesives over sutures and staples is significant in Cosmetic surgeries, General surgeries, Neurosurgery, Urological surgeries and Cardiovascular surgeries due to the availability of a large number of products from major and minor companies. The advantages like better cosmetic outcome with minimal scarring, reduced surgical site infection and reduced surgery time are driving the use of sealants and adhesives in these surgeries. However, the cost of surgical sealants and adhesives are very high compared to sutures and staples which is compelling patients and surgeons to opt for traditional closure products especially in emerging countries, but this scenario can change in future with the reduction in the cost, technological advancements and acceptance of sealants and adhesives over sutures and staples.
Geographically, North America commanded the largest share of the surgical sealants and adhesives global market followed by Europe, Asia-Pacific and ROW. High investments in healthcare infrastructures, advanced healthcare facilities, increasing ageing population, increasing surgical procedural volume, availability of Medicare and third party insurance facilities and easy availability of skilled professionals in this region has led to hold a major share in this market. Asia-Pacific is the fastest growing region mainly driven by countries like India and China which are expected to be the future investment destination for companies because of government funding and their large patient populace base. Thailand and India are growing medical tourism destinations which offer significantly lower cost for surgeries and treatment compared to U.S and U.K.
Surgical sealants and adhesives global market is consolidated, the top companies like Baxter International Inc. (U.S.), Johnson & Johnson (Ethicon) (U.S.), Takeda Pharmaceutical Company Ltd. (Japan), Becton, Dickinson & Company (C.R.Bard) (U.S.), B.Braun Melsungen AG (Germany) occupy major share in the global market. Companies in this market are coming up with innovative technologies and products for entering or to maintaining their leadership position in surgical sealants and adhesives market. For instance, Xcede Technologies, Inc., a subsidiary of Dynasil Corporation of America (U.S.) develops hemostatic and sealant products for surgical applications with unique technology and intellectual property (IP) protection. Also, companies are competing with each other by strategic acquisitions to expand their market. For instance, Mallinckrodt Plc, acquired the global portfolio of three commercial-stage sealants and hemostasis from The Medicines Company (U.S.). The portfolio includes RECOTHROM Thrombin topical (Recombinant), PreveLeak Surgical Sealant, and RAPLIXA (Fibrin Sealant (Human)). The inclusion of these products will expand Mallinckrodt’s surgical sealant and adhesive product portfolio.
Emerging players of this market include Adhezion Biomedical, LLC. (U.S.), Starch Medical, Inc. (U.S.), Vivostat A/S (Denmark), Tissuemed Ltd. (U.K.), Western Biomedical (Australia), GEM SRL (Italy), Hyperbranch Medical Technology, Inc. (U.S.), Gecko Biomedical (France), Hyperbranch Medical Technology, Inc. (U.S.), Chemence Medical, Inc. (U.S.), IBC Pharmaceuticals Ltd. (India), Sealantis Ltd (Israel), Polyganics (Netherland), OptMed, Inc. (U.S.), and others.
Some of the major players in Surgical sealants and adhesives market include Baxter International Inc. (U.S.), Johnson & Johnson (Ethicon) (U.S.), Becton, Dickinson & Company (C.R.Bard) (U.S.), B.Braun Melsungen AG (Germany), Medtronic Plc (Ireland), Cryolife, Inc. (U.S.), Mallinckrodt Plc (U.K.), Advanced Medical Solutions Group Plc (U.K.), Takeda Pharmaceutical Company Ltd. (Japan), Cohera Medical, Inc. (U.S.).
For more information please visit our website: https://www.iq4i.com/reports-category/medicaldevices/r/173
Write to us: bd@iq4i.com